Goldman, KKR Among Lenders of €1.4 Billion PIK Debt for Stada

Goldman Sachs Asset Management and KKR & Co., alongside PSP Investments and Arcmont Asset Management, are providing approximately €1.4 billion in Payment-in-Kind (PIK) debt to facilitate CapVest Partners' acquisition of a majority stake in German drugmaker Stada Arzneimittel AG. The deployment of this expensive debt type signals a highly leveraged transaction.

Analysis

A consortium of institutional lenders, including Goldman Sachs Asset Management and KKR & Co., is providing €1.4 billion in Payment-in-Kind (PIK) debt to finance CapVest Partners' acquisition of a majority stake in German drugmaker Stada Arzneimittel AG. The deployment of PIK debt, noted as one of the most expensive forms of financing, is significant as it allows the borrower to defer cash interest payments by instead issuing more debt. This structure indicates a highly leveraged transaction, suggesting the sponsors anticipate strong future cash flow generation or a high-multiple exit to service the costly, compounding debt. The participation of prominent credit investors like Goldman, KKR, PSP Investments, and Arcmont Asset Management underscores a continued appetite within private credit markets for high-yield, complex instruments, and signals confidence in the underlying asset's ability to support this aggressive capital structure. The transaction serves as a key data point on the state of the European leveraged finance market, particularly in the healthcare sector, where private equity sponsors are utilizing sophisticated debt instruments to execute large-scale buyouts.

Key Decisions for Investors

• For investors in Goldman Sachs (GS) and KKR, this deal highlights their private credit arms' continued activity in the high-yield space, deploying capital into complex, subordinated debt instruments to generate returns, which can be viewed as an indicator of their risk appetite and deal-sourcing capabilities.
• Credit market participants should note that the successful placement of a large PIK debt facility signals that private capital remains available for highly leveraged M&A, though at a significant cost, reflecting lender confidence in sponsored transactions despite the riskier debt structure.
• Investors tracking the healthcare sector should view this highly leveraged financing for Stada as a sign that private equity sponsors see significant upside in the drugmaker's future performance, which will be necessary to justify and service the expensive PIK debt.